Alexandre Nguimfack, Eudoxia Filipe, Dercio Filimao, José Mizela, Erica Bila, Mercia Matsinhe, Maria Inês Tomo de Deus, Irenio Gaspar, Maria Ruano, Luis Armando, Orrin Tiberi
{"title":"2023年10月至12月,莫桑比克选定保健单位的晚期艾滋病毒疾病。","authors":"Alexandre Nguimfack, Eudoxia Filipe, Dercio Filimao, José Mizela, Erica Bila, Mercia Matsinhe, Maria Inês Tomo de Deus, Irenio Gaspar, Maria Ruano, Luis Armando, Orrin Tiberi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Advanced HIV Disease (AHD) is a remaining hurdle in the care and treatment cascade in Mozambique and has the potential to delay Mozambique's progress towards the UNAIDS 95-95-95 goals for 2025. An improved understanding of the prevalence and demographics of people with AHD is critical to address this important condition.</p><p><strong>Methods: </strong>Data were reviewed from October to December 2023 from the 79 health facilities at a national level implementing the AHD diagnosis and treatment package at the national level.</p><p><strong>Results: </strong>Overall, 36% (7.811/21.452) of people living with HIV new initiated or reinitiated on antiviral treatment had a CD4 test, of which 1.986 were diagnosed with AHD (25%). Most of the diagnosed cases were in people living with HIV that were newly initiated (1.814) versus those being reinitiated (179).</p><p><strong>Conclusion: </strong>The low coverage of CD4 testing in eligible patients is an obstacle to the early identification of AHD patients and the reduction of mortality, and consequently a barrier to HIV elimination in Mozambique.</p>","PeriodicalId":520426,"journal":{"name":"Revista mocambicana de ciencias de saude","volume":"10 2","pages":"18-22"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848748/pdf/","citationCount":"0","resultStr":"{\"title\":\"Doença Avançada por HIV em Unidades Sanitárias Seleccionadas em Moçambique, Outubro-Dezembro de 2023.\",\"authors\":\"Alexandre Nguimfack, Eudoxia Filipe, Dercio Filimao, José Mizela, Erica Bila, Mercia Matsinhe, Maria Inês Tomo de Deus, Irenio Gaspar, Maria Ruano, Luis Armando, Orrin Tiberi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Advanced HIV Disease (AHD) is a remaining hurdle in the care and treatment cascade in Mozambique and has the potential to delay Mozambique's progress towards the UNAIDS 95-95-95 goals for 2025. An improved understanding of the prevalence and demographics of people with AHD is critical to address this important condition.</p><p><strong>Methods: </strong>Data were reviewed from October to December 2023 from the 79 health facilities at a national level implementing the AHD diagnosis and treatment package at the national level.</p><p><strong>Results: </strong>Overall, 36% (7.811/21.452) of people living with HIV new initiated or reinitiated on antiviral treatment had a CD4 test, of which 1.986 were diagnosed with AHD (25%). Most of the diagnosed cases were in people living with HIV that were newly initiated (1.814) versus those being reinitiated (179).</p><p><strong>Conclusion: </strong>The low coverage of CD4 testing in eligible patients is an obstacle to the early identification of AHD patients and the reduction of mortality, and consequently a barrier to HIV elimination in Mozambique.</p>\",\"PeriodicalId\":520426,\"journal\":{\"name\":\"Revista mocambicana de ciencias de saude\",\"volume\":\"10 2\",\"pages\":\"18-22\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848748/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista mocambicana de ciencias de saude\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mocambicana de ciencias de saude","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Doença Avançada por HIV em Unidades Sanitárias Seleccionadas em Moçambique, Outubro-Dezembro de 2023.
Introduction: Advanced HIV Disease (AHD) is a remaining hurdle in the care and treatment cascade in Mozambique and has the potential to delay Mozambique's progress towards the UNAIDS 95-95-95 goals for 2025. An improved understanding of the prevalence and demographics of people with AHD is critical to address this important condition.
Methods: Data were reviewed from October to December 2023 from the 79 health facilities at a national level implementing the AHD diagnosis and treatment package at the national level.
Results: Overall, 36% (7.811/21.452) of people living with HIV new initiated or reinitiated on antiviral treatment had a CD4 test, of which 1.986 were diagnosed with AHD (25%). Most of the diagnosed cases were in people living with HIV that were newly initiated (1.814) versus those being reinitiated (179).
Conclusion: The low coverage of CD4 testing in eligible patients is an obstacle to the early identification of AHD patients and the reduction of mortality, and consequently a barrier to HIV elimination in Mozambique.